Crohn's that keeps coming back: where cells genuinely fit
This is a composite decision situation, not a real patient, testimonial or individual treatment recommendation.
Biologic number two is losing its grip, the specialist mentions surgery words you did not want in your vocabulary, and somewhere in a patient forum “stem cells” came up — with unusually mixed reactions. Crohn's is a special case in this field, and knowing exactly where the evidence lives will save you from paying for the wrong version of it.
What the data says for this situation
Crohn's disease is one of the few conditions with an actually approved cell therapy: allogeneic adipose MSCs for complex perianal fistulas earned European approval after randomised trials showed higher healing rates than control. That is the narrow, legitimate island. Around it sits a wide investigational sea — our snapshot counts 52 MSC and 18 HSCT studies, including intensive HSCT protocols for severe refractory disease, which trials show can induce remissions at the price of serious toxicity. Clinics abroad blur all of this into “stem cells for Crohn's”; the approved product treats fistulas specifically, not luminal disease, and the HSCT route belongs in specialist centres inside trials.
Questions worth asking any provider
- Is my case the fistula scenario the approved product actually covers?
- If HSCT is proposed: what trial, what centre experience, what toxicity data?
- For MSC infusions: which published study in luminal Crohn's justifies the price?
- How does this sequence with the biologics I have left?
Red flags specific to this situation
- The approved fistula product's data quoted to sell IV infusions
- HSCT offered outside specialist haematology settings
- “Immune reset” language without any trial registration
Cost context
The approved fistula therapy runs through hospital channels, not tourism packages. Commercial IV-MSC packages abroad (€8,000–€20,000) borrow its credibility while sharing none of its evidence.
FAQ
Is there an approved stem cell treatment for Crohn's?
Yes — allogeneic MSCs for complex perianal fistulas in Europe. It does not treat inflammation along the gut itself.
Can HSCT put Crohn's in remission?
Trials show it can in severe refractory cases, with substantial toxicity — a specialist-centre, trial-setting decision.
→ Build questions for a specific provider · → Cost calculator
Interactive/editorial page by the StemCellAtlas research team. Where registry or literature counts appear, they use the dated 2026-08-29 snapshot. Browser-only tools do not send or store answers. Page generated 2026-08-29. See our editorial standards.